ONCT vs. ELDN, MIST, ONCY, MRNS, SCYX, KRON, AFMD, ALLK, CMRX, and BYSI
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Eledon Pharmaceuticals (ELDN), Milestone Pharmaceuticals (MIST), Oncolytics Biotech (ONCY), Marinus Pharmaceuticals (MRNS), SCYNEXIS (SCYX), Kronos Bio (KRON), Affimed (AFMD), Allakos (ALLK), Chimerix (CMRX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical preparations" industry.
Eledon Pharmaceuticals (NASDAQ:ELDN) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
Oncternal Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncternal Therapeutics received 5 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.22% of users gave Eledon Pharmaceuticals an outperform vote while only 30.39% of users gave Oncternal Therapeutics an outperform vote.
56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are held by institutional investors. 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for Oncternal Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.96 beat Eledon Pharmaceuticals' score of 0.93 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Eledon Pharmaceuticals' net margin of -3,160.73%. Oncternal Therapeutics' return on equity of -45.60% beat Eledon Pharmaceuticals' return on equity.
Eledon Pharmaceuticals currently has a consensus target price of $11.67, suggesting a potential upside of 295.48%. Oncternal Therapeutics has a consensus target price of $28.33, suggesting a potential upside of 301.89%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than Eledon Pharmaceuticals.
Summary
Eledon Pharmaceuticals beats Oncternal Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Oncternal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
